Trial Profile
A Randomized, Double-blind, Third Party (Sponsor) Open, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of HIP2B in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2012
Price :
$35
*
At a glance
- Drugs Human proislet peptide (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors CureDM
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2012 New trial record